CC 케모카인 수용체 5형(CCR5) 시장 규모, 점유율 및 성장 분석 : 약제 유형별, 적응증별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Cc Chemokine Receptor Type 5 Market size was valued at USD 1.46 Billion in 2024 and is poised to grow from USD 1.6 Billion in 2025 to USD 3.39 Billion by 2033, growing at a CAGR of 9.8% during the forecast period (2026-2033).

The global CC chemokine receptor type 5 market is experiencing robust growth driven by the development of therapeutic agents that inhibit or modulate this receptor for conditions such as HIV infection, inflammatory disorders, and various cancers. With CCR5's critical role in HIV-1 entry and immune cell movement, it has attracted considerable interest from biotechnology firms. The landscape has evolved significantly since the introduction of CCR5 antagonists and recent pipeline activity reflects increased investments from both startups and major pharmaceutical companies in innovative strategies like gene editing and antibody development. The expanding clinical validation of CCR5 blockade, particularly in oncology and autoimmune diseases, has led to substantial investment and regulatory momentum, further accelerating research and development and broadening the market's reach among diverse patient populations.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cc Chemokine Receptor Type 5 market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cc Chemokine Receptor Type 5 Market Segments Analysis

Global cc chemokine receptor type 5 market is segmented by drug type, indication, route of administration, end user and region. Based on drug type, the market is segmented into small molecule antagonists and monoclonal antibodies. Based on indication, the market is segmented into HIV infection, oncology, autoimmune & inflammatory diseases and other indications. Based on route of administration, the market is segmented into oral and injectable. Based on end user, the market is segmented into hospitals, specialty clinics and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cc Chemokine Receptor Type 5 Market

The increasing emphasis on immunotherapy has led to significant research into CCR5 as a potential therapeutic target, driving pharmaceutical companies to investigate new agents. This scientific exploration fosters a pipeline of innovative products, which in turn attracts investment and encourages collaboration between academia and industry. As researchers identify wider applications for CCR5 inhibitors, the perceived value of these treatments grows, resulting in faster development timelines and greater regulatory focus. This environment instills confidence among market participants, resulting in expanded product offerings and heightened market engagement. These factors together contribute to a robust growth trajectory for the market.

Restraints in the Global Cc Chemokine Receptor Type 5 Market

The global CCR5 market faces significant challenges due to the fragmented regulatory frameworks surrounding gene-editing technologies. This inconsistency across jurisdictions creates uncertainty for developers of CCR5-targeted therapies that utilize CRISPR or similar methods. Unclear approval processes and varying safety criteria lead to delays in the initiation of clinical trials while also escalating compliance costs. Companies are forced to dedicate substantial resources to navigating these differing standards, which can dissuade investment and prolong product launch timelines. This regulatory complexity ultimately inhibits market growth as stakeholders await the establishment of harmonized guidelines that would clarify expectations and mitigate developmental risks, thereby restricting the timely entry of innovative CCR5 products.

Market Trends of the Global Cc Chemokine Receptor Type 5 Market

The Global CCR5 Chemokine Receptor Type 5 market is witnessing a significant trend towards the integration of immunotherapy strategies within oncology. With an increasing acknowledgment of CCR5 antagonists' role in modifying tumor microenvironments and influencing immune cell dynamics, pharmaceutical companies are forming strategic alliances with biotech firms to include CCR5 inhibitors in combination therapies. This trend encompasses the co-administration of CCR5 inhibitors with checkpoint inhibitors, CAR-T therapies, and vaccine strategies, thereby improving therapeutic outcomes and expanding the scope of treatable patient demographics. As these collaborations evolve, market players foresee a swift adoption of CCR5-targeted treatments, cementing their position as vital components in the future of cancer care innovation.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global CC Chemokine Receptor Type 5 Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Small Molecule Antagonists
• Monoclonal Antibodies

Global CC Chemokine Receptor Type 5 Market Size by Indication & CAGR (2026-2033)

• Market Overview
• HIV Infection
• Oncology
• Autoimmune & Inflammatory Diseases
• Other Indications

Global CC Chemokine Receptor Type 5 Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global CC Chemokine Receptor Type 5 Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Research Institutes

Global CC Chemokine Receptor Type 5 Market Size & CAGR (2026-2033)

• North America (Drug Type, Indication, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Type, Indication, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Indication, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Indication, Route of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Indication, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViiV Healthcare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emcure Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laurus Labs Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apex Laboratories Private Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofarma Laboratorios S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations